Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C M Jespersen

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Journal of Cardiovascular Pharmacology|January 1, 1991
The effect of verapamil on major events in patients with exercise-induced ischemia recovering from acute myocardial infarction: a review. The Danish Study Group on Verapamil in Myocardial InfarctionC M Jespersen
Cardiovascular Drugs and Therapy|April 8, 2000
Verapamil in acute myocardial infarction. The rationales of the VAMI and DAVIT III trialsC M Jespersen
European Journal of Clinical Pharmacology|January 1, 1990
Assessment of blindness in the Danish Verapamil Infarction Trial II (DAVIT II). Danish Study Group on Verapamil in Myocardial InfarctionC M Jespersen
Ugeskrift for Laeger|May 21, 1990
[Isoptin Retard. Pharmacokinetics and pharmacodynamics in patients with angina pectoris]C M Jespersen
Cardiologia (Rome, Italy)|December 1, 1995
Is a combination of verapamil and an ACE-inhibitor the optimal solution in ischaemic heart failure?C M Jespersen
Ugeskrift for Laeger|July 6, 1987
[Arterial blood pressure during gestagen treatment]C M Jespersen
Cardiovascular Drugs and Therapy|October 12, 1999
Verapamil in acute myocardial infarction. The rationales of the VAMI and DAVIT III trialsC M Jespersen
European Heart Journal|August 1, 1995
Anti-ischaemic intervention with verapamil in patients recovering from acute myocardial infarctionC M Jespersen
The American Journal of Cardiology|June 20, 1996
Anti-ischemic intervention as prognosis improvement in patients with coronary artery disease, with special focus on verapamilC M Jespersen
Cardiovascular Drugs and Therapy|December 1, 1994
Role of ischemia in postinfarction heart failure: hypothetical considerations based on use of verapamil in the DAVIT II Study. Danish Study Group on Verapamil in Myocardial InfarctionC M Jespersen
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Journal of Cardiovascular Pharmacology|January 1, 1991
The effect of verapamil on major events in patients with exercise-induced ischemia recovering from acute myocardial infarction: a review. The Danish Study Group on Verapamil in Myocardial InfarctionC M Jespersen
Cardiovascular Drugs and Therapy|April 8, 2000
Verapamil in acute myocardial infarction. The rationales of the VAMI and DAVIT III trialsC M Jespersen
European Journal of Clinical Pharmacology|January 1, 1990
Assessment of blindness in the Danish Verapamil Infarction Trial II (DAVIT II). Danish Study Group on Verapamil in Myocardial InfarctionC M Jespersen
Ugeskrift for Laeger|May 21, 1990
[Isoptin Retard. Pharmacokinetics and pharmacodynamics in patients with angina pectoris]C M Jespersen
Cardiologia (Rome, Italy)|December 1, 1995
Is a combination of verapamil and an ACE-inhibitor the optimal solution in ischaemic heart failure?C M Jespersen
Ugeskrift for Laeger|July 6, 1987
[Arterial blood pressure during gestagen treatment]C M Jespersen
Cardiovascular Drugs and Therapy|October 12, 1999
Verapamil in acute myocardial infarction. The rationales of the VAMI and DAVIT III trialsC M Jespersen
European Heart Journal|August 1, 1995
Anti-ischaemic intervention with verapamil in patients recovering from acute myocardial infarctionC M Jespersen
The American Journal of Cardiology|June 20, 1996
Anti-ischemic intervention as prognosis improvement in patients with coronary artery disease, with special focus on verapamilC M Jespersen
Cardiovascular Drugs and Therapy|December 1, 1994
Role of ischemia in postinfarction heart failure: hypothetical considerations based on use of verapamil in the DAVIT II Study. Danish Study Group on Verapamil in Myocardial InfarctionC M Jespersen
Pageof 4